{"id":880988,"date":"2026-10-13T16:02:14","date_gmt":"2026-10-13T16:02:14","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/880988\/"},"modified":"2026-10-13T16:02:14","modified_gmt":"2026-10-13T16:02:14","slug":"johnson-johnson-jnj-earnings-q3-2026","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/880988\/","title":{"rendered":"Johnson &#038; Johnson (JNJ) earnings Q3 2026"},"content":{"rendered":"<p><img decoding=\"async\" class=\"InlineVideo-videoThumbnail\" src=\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2026\/10\/108402711-17918889961791888992-48971327504-1080pnbcnews.jpg\" alt=\"Johnson &amp; Johnson CFO Joseph Wolk on the company&#x2019;s Q3 results\"\/><\/p>\n<p><a href=\"https:\/\/www.cnbc.com\/quotes\/JNJ\/\" rel=\"nofollow noopener\" target=\"_blank\">Johnson &amp; Johnson<\/a> reported a slightly higher-than-expected profit on Tuesday, driven by strong sales of its immune disease treatment, Tremfya, and said it plans to spin off its hips-and-knees business next year.<\/p>\n<p>The company said late last year it intended to separate its orthopedics unit, DePuy Synthes, into a standalone company, marking its second major spinoff as it sharpens its focus on higher-growth healthcare segments.<\/p>\n<p>Chief Financial Officer Joe Wolk said on a conference call to discuss company results that J&amp;J remains on track for a mid-2027 separation of DePuy Synthes.<\/p>\n<p>&#8220;Given the way DePuy Synthes is performing&#8230; we are leaning towards a spin as being the best option to create long-term value for Johnson &amp; Johnson shareholders. That has always been our base plan, and we are confident that it can be successfully executed,&#8221; he said.<\/p>\n<p>Apollo Global Management is in talks to acquire the orthopedics unit in a \u200bdeal that could value it at close to $20 billion, Bloomberg News reported in September.<\/p>\n<p>J&amp;J shares were off about 2% before the bell.<\/p>\n<p><a id=\"headline0\"\/>Middle East conflict weighs on MedTech<\/p>\n<p>Wolk, in an interview, told Reuters the Middle East conflict, austerity measures in Europe and pricing in China continued to weigh on results internationally, &#8220;but maybe in a little bit more pronounced way.&#8221;<\/p>\n<p>He said the Middle East conflict, which has driven up fuel costs, has not yet affected the company&#8217;s costs but has hurt sales in the region.<\/p>\n<p>&#8220;These are countries that still value and actually want premium healthcare systems, think Kuwait, UAE, Saudi Arabia. They pride themselves on having solid healthcare, very good healthcare,&#8221; Wolk said. &#8220;But their budgets now are being resourced and allocated towards defense.&#8221;<\/p>\n<p>Medical technology division sales rose 2.5% to $8.6 billion overall, missing analysts&#8217; estimates of $8.71 billion, according to LSEG data. Outside the US, sales were essentially flat.<\/p>\n<p>The company raised its full-year sales forecast to about $101.2 billion at the midpoint, from $101.1 billion previously. It increased its adjusted earnings forecast range with a new midpoint of $11.10 per share, up from $11.04.<\/p>\n<p>Sales at J&amp;J&#8217;s Abiomed heart pump business remained slow after a UK study earlier this year raised questions about using Impella pumps in certain high-risk \u200bcoronary procedures.<\/p>\n<p>The MedTech miss was largely in cardio and surgery, J.P. Morgan analyst Chris Schott said.<\/p>\n<p>Quarterly pharmaceutical sales jumped 7.7% to $16.76 billion.<\/p>\n<p>&#8220;While the results overall are generally in line with expectations, we believe investors will be disappointed in some of the details within the results,&#8221; said Guggenheim analyst Vamil Divan, noting that the MedTech results were &#8220;somewhat disappointing.&#8221;<\/p>\n<p>Divan pointed to strong sales of older products such as Stelara and Simponi, adding that Tremfya and Tecvayli, a multiple myeloma treatment, were the only newer, strategically important products that appear to have meaningfully beaten expectations.<\/p>\n<p>Tremfya sales for Crohn&#8217;s disease and other autoimmune conditions rose 68% to $2.4 billion, beating analyst estimates of about $2.2 billion, while Stelara sales, which face generic competition, fell 54% to $716 million, still well above diminished Wall Street expectations of $591 million. Tremfya has increasingly replaced lost Stelara revenue following recent approvals in inflammatory bowel diseases.<\/p>\n<p>Sales of blood cancer treatment Darzalex rose about 16% to $4.24 billion, short of analysts&#8217; expectations of $4.4 billion.<\/p>\n<p>The company posted third-quarter revenue of $25.4 billion, above estimates of $25.28 billion, and adjusted earnings of $2.59 per share, topping Wall Street expectations by 5 cents.<\/p>\n<p><a href=\"https:\/\/www.google.com\/preferences\/source?q=https:\/\/www.cnbc.com\/\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Johnson &amp; Johnson reported a slightly higher-than-expected profit on Tuesday, driven by strong sales of its immune disease&hellip;\n","protected":false},"author":2,"featured_media":880989,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[59],"tags":[16156,5681,28,122,8084,97,252,2601,253,223504,167668,2918,74],"class_list":["post-880988","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health-care","tag-apollo-global-management-inc","tag-breaking-news-technology","tag-business","tag-business-news","tag-earnings","tag-health","tag-health-care","tag-health-care-industry","tag-healthcare","tag-ishares-u-s-healthcare-etf","tag-ishares-u-s-medical-devices-etf","tag-johnson-johnson","tag-technology"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/880988","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=880988"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/880988\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/880989"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=880988"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=880988"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=880988"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}